LINC01338: A Potential Drug Target and Biomarker (G102546175)

Target Name: LINC01338

NCBI ID: G102546175

LINC01338

Other Name(s): Long intergenic non-protein coding RNA 1338 | long intergenic non-protein coding RNA 1338

LINC01338: A Potential Drug Target and Biomarker

LINC01338 is a long intergenic non-protein coding RNA (lncRNA) with a length of 212 nucleotides. It is found in various tissues and has been identified as a potential drug target and biomarker. LINC01338 is a non-coding RNA which can interact with protein-coding genes, playing a role in gene regulation and cell signaling. The study of lncRNA has become an attractive area of research in recent years due to its potential role in various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

Potential Drug Target

LINC01338 has been identified as a potential drug target due to its unique structure and its interaction with protein-coding genes. The non-coding RNA has been shown to interact with several protein-coding genes, including the transcription factor ASXL1 and the protein tyrosine kinase TPK1. These interactions suggest that LINC01338 may play a role in the regulation of gene expression and may be a useful target for small molecule inhibitors.

In addition to its potential as a drug target, LINC01338 has also been shown to be a potential biomarker for various diseases. The expression of LINC01338 has been shown to be regulated in various tissues and conditions, including cancer, neurodegenerative diseases, and psychiatric disorders. The levels of LINC01338 have also been shown to be associated with the development of certain diseases, such as Alzheimer's disease and depression.

Biomarker Potential

The potential use of LINC01338 as a biomarker has been studied in various conditions, including cancer, neurodegenerative diseases, and psychiatric disorders. Studies have shown that LINC01338 is expressed in various tissues and conditions, including cancer cells, neurons, and glial cells in neurodegenerative diseases. Additionally, LINC01338 has been shown to be expressed in the brains of individuals with Alzheimer's disease and depression.

The potential use of LINC01338 as a biomarker for these diseases makes it an attractive target for small molecule inhibitors. By inhibiting the expression of LINC01338, researchers hope to reduce the levels of this RNA in various tissues and conditions, including cancer cells, neurons, and glial cells in neurodegenerative diseases, and brain cells in psychiatric disorders.

Conclusion

LINC01338 is a long intergenic non-protein coding RNA with potential as a drug target and biomarker. Its unique structure and interaction with protein-coding genes make it an attractive target for small molecule inhibitors. The potential use of LINC01338 as a biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders makes it an attractive target for researchers. Further studies are needed to fully understand the potential of LINC01338 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1338

The "LINC01338 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01338 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets